

**Progress of actions arising from the Boards' meeting held on 8 May 2026
and any outstanding actions from previous UHL meetings**

Item no.	Minute Ref:	Action	Lead	By When	Progress Update	RAG status*
8 May 2026						
3.3i	22/26/3	The Director of Continuous Improvement (UHN) undertook to work with Chief Operating Officers to review performance indicator definitions for length of stay to account for possible differences between UHN and UHL.	B Taylor	August 2026	To be picked up as part of review of metric definitions for the joint IPR	4
3.3ii	22/26/3	To provide a detailed projected timeline to bring NGH Mortality indicators within expected levels.	H Nemade	Tbc	Verbal update to be provided	1
3.3iii	22/26/3	Updated Patient Safety and Incident Response Plans to be provided	H Nemade / G Xu	Tbc	UHL Plan 2026-28 approved at 9 April Board.	4
3.3iv	22/26/3	Variability in staff availability due to sickness and other factors was also highlighted across professions and specialties; the Boards requested that the People Committees provide particularly close oversight of these issues.	P Kirkpatrick / C Teeney	July 2026	To be incorporated into Chief People Officers' reports to the July people committees	5
3.4.4 i	22/26/4	The UHL Board requested the Finance and Investment Committee review benefits realization of the new Endoscopy centre for capacity and activity	S Barton	Tbc	A formal Post Implementation review will be carried out. This will be reported through the Finance and Investment Committee in due course. In the meantime we will continue to monitor productivity and outputs through the monthly performance and finance reports.	4
3.4.4 ii	22/26/4	The UHL Board requested that community provision and cross-site working be included within scope of the next stages of the ophthalmology review	H Hendley	September 2026	To be included in the ophthalmology report to Operational Performance Committee, with escalations managed through reports to Boards	4
6.1	25/26/1	To clarify oversight arrangements for the UHN Community Engagement Strategy as part of the current review of committees being led by the Vice-Chairs	B Cassidy	On hold		1
6.2	25/26/2	For UHL Green Plan updates to contain improved visibility of delivery progress and benefits	J Hogg	August 2026	To be incorporated into the next report for the Finance and Investment Committee	4

* Both numerical and colour keys are to be used in the RAG rating. If target dates are changed this must be shown using ~~strike through~~ so that the original date is still visible.

RAG Status Key:	5	Complete	4	On Track	3	Some Delay – expected to be completed as planned	2	Significant Delay – unlikely to be completed as planned	1	Not yet commenced
------------------------	----------	-----------------	----------	-----------------	----------	---	----------	--	----------	--------------------------

Boards in Common Paper B

Item no.	Minute Ref:	Action	Lead	By When	Progress Update	RAG status*
9 April 2026						
2a	18/26/3	To review and put in place improvements in the cancer pathway, relating to engagement with families.	GpCN DoC&E (UHL & UHN) J Hogg, E Casteleijn, S O'Neill	July 2026 QC	Will be built into the quarterly cancer report for Quality Committees.	4
2c	18/26/3	To develop a single group Integrated Performance Report	DoCI (UHN)/ COO (UHL) B Taylor	BiC 8.10.26	Joint executives have considered and recommended metrics for the Joint IPR to committees for approval. Development of format and alignment of metric definitions to commence in preparation for Joint IPR to be presented at October Board.	4
2d	18/26/3	To consider how to incorporate more up to date data within the Integrated Performance Report.	DoCI (UHN)/ COO (UHL) B Taylor	BiC 8.10.26	As development of the Joint IPR commences, timeliness of data and validation processes will be reviewed in line with committee dates. Review of what access can be made available to the Board of more real time data.	4
3	18/26/4	UHL Quality Committee Escalation Report To consider the impact of AI in terms of growth of complexity in complaints and legal issues and determine if policy changes were required in response.	GpCDIO / GpCN / DCLA (UHL) W Monaghan / J Hogg / B Cassidy	QC after quarter 2	Will be incorporated into the quarter 2 patient experience update.	4
4	19/26/1	Group Perinatal Report and Dashboards To provide greater clarity on key, high level risks in future reports.	GpCN J Hogg	June 2026	To be reflected from June 2026.	4
5	20/26/2	Group Research and Innovation Report To present a proposal to Boards in Common for a single group Research and Innovation framework.	MD (UHN & UHL) / DoR&I H Nemade	BiC 7.8.26	A Group research strategy is in preparation.	4

* Both numerical and colour keys are to be used in the RAG rating. If target dates are changed this must be shown using ~~strike through~~ so that the original date is still visible.

RAG Status Key:	5	Complete	4	On Track	3	Some Delay – expected to be completed as planned	2	Significant Delay – unlikely to be completed as planned	1	Not yet commenced
------------------------	----------	-----------------	----------	-----------------	----------	---	----------	--	----------	--------------------------

Boards in Common Paper B

Item no.	Minute Ref:	Action	Lead	By When	Progress Update	RAG status*
			/ G Xu / N Brunskill			
5a	20/26/2	To include greater detail in future reports of trial / research outcomes.	MD (UHN & UHL) / DoR&I H Nemade / G Xu / N Brunskill	BiC 7.8.26	Up to 1000 clinical trials are open across the Group at any one time. It is not possible to provide outcomes for all. However, trial outcome highlights of particular interest / importance will be provided in future reports to Board.	4
5b	20/26/2	To measure trial access across constituent populations across the Group area in order to inform possible approaches for wider inclusion in trials.	MD (UHN & UHL) / DoR&I H Nemade / G Xu / N Brunskill	BiC 7.8.26	Inclusion work takes place widely across our research infrastructure. NIHR funded infrastructure has an established inclusion strategy. Where practical and where trial data confidentiality permits, an indication of participant background can be included in future reports to Board.	4

Progress of outstanding actions arising from University Hospitals of Leicester NHS Trust Board

12 February 2026

6	34/26/1	Perinatal Quality Surveillance Scorecard / Perinatal Assurance Committee (PAC) Highlight Report To include feedback from conversations with partners on infant mortality prevention in the next report.	CN J Hogg	TB April 2026	To be scheduled accordingly – detail will be incorporated into a spotlight piece within the Perinatal Quality Surveillance Scorecard.	5
7	35/26/1	Freedom to Speak Up To include details of anonymous complaints in future reports.	DCLA B Cassidy	June 2026	Included in report at agenda item 6.2	5

11 December 2025

8	299/25/1	BAF & Significant Risk Register To explore ways of demonstrating that mitigating actions are showing a beneficial impact on a risk, such as a progression score.	DCLA B Cassidy	TB June 2026	Included in report at agenda item 7.1	5
---	----------	--	-------------------	-----------------	---------------------------------------	---

8 May 2025 (approvals recorded in the formal minutes only)

9	112/25/1	Freedom to Speak Up - Q4 and Annual Report To provide a progress report to the PCC on the recommendations made and provide an update through the escalation report to the Board	DCLA B Cassidy	TB June 26	As part of the FTSU annual reporting in May, a review of the recommendations is set out in the escalation report from the PCC.	5
---	----------	---	-------------------	---------------	--	---

* Both numerical and colour keys are to be used in the RAG rating. If target dates are changed this must be shown using ~~strike through~~ so that the original date is still visible.

RAG Status Key:	5	Complete	4	On Track	3	Some Delay – expected to be completed as planned	2	Significant Delay – unlikely to be completed as planned	1	Not yet commenced
------------------------	----------	-----------------	----------	-----------------	----------	---	----------	--	----------	--------------------------